Pixuvri’s multitarget approach, which targets proteins like BubR1, Cdc20, MAD2, and TPX2, could circumvent these resistance mechanisms, offering a more effective strategy against drug-resistant cancers. This evidence concerns the gene TPX2 and cancer.